- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Bioalliance Pharma SA (Paris:BIO) (Euronext Paris, ISIN code: FR0010095596-BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, today announced that Madame Dominique Costantini, President of the company's Executive Board, had been awarded the Knight of the Legion of Honor insignia by Professor Claude Griscelli, a former Director of France's INSERM national institute of health and a member of the country's State Council.
The award has been made in recognition of an exceptional physician, researcher and company executive with co-founder of BioAlliance Pharma, Gilles Avenard MD. Professor Claude Griscelli recounted some of the highlights of Dominique Costantini's professional career: "I first met Dominique when she was a student in my department at Necker Children's Hospital. She then moved into the pharmaceutical industry, where I witnessed the development of her tenacity, her sense of responsibility and, above all, her commitment to getting results - qualities which have enabled her to build BioAlliance Pharma and get its first drug onto the market in under 7 years".
"I am very honored because this insignia is also an award for a growing SME, which I would like to share with Gilles Avenard, my business partner and co-founder of BioAlliance Pharma, and all the company's staff and academic partners, without whom this wonderful corporate adventure would not have been possible," emphasized Dominique Costantini.
Within less than 10 years, BioAlliance Pharma has created an original business model, an integrated pharmaceutical laboratory specialized to the hospital, focusing on patients' needs and quality of life in oncology and infectious diseases.
About Bioalliance Pharma SA
BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address drug resistance issues. BioAlliance Pharma has launched its first portfolio product (Loramyc®) in France and, more recently, in the UK, Germany and Denmark, and has already received European Marketing Authorizations in Belgium and Luxemburg. The product has also completed a pivotal Phase III clinical trial in the United States in oropharyngeal candidiasis. The company is also performing a Phase III trial in labial herpes with acyclovir Lauriad® (which is based on the same Lauriad® muco-adhesive technology as Loramyc®, enabling targeted release at the disease site). BioAlliance Pharma also has a second technology (the Transdrug® nanoparticle technology, designed specifically for intracellular targeting) and, furthermore, is developing a new therapeutic entities program in oncology and infectious disease. BioAlliance Pharma has established several strategic alliances for commercializing Loramyc®, with agreements in 2007 for Europe (with the SpeBio joint venture) and the United States (with Par Pharmaceutical) and in 2008 for Asia (Korea, Malaysia, Singapore and Taiwan with Handok Pharmaceuticals and then China with Novamed). In May and August 2008, the company expanded its product portfolio by acquiring the Europe commercial rights to, respectively, ondansetron Oral Spray (OS) from NovaDel Pharma Inc. (Amex: NVD) and ondansetron RapidFilmTM from APR/Labtec.
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 11 2008 under the number R. 08-021, which is available on the AMF website (www.amf-france.org) or on BioAlliance Pharma S.A.'s website (www.bioalliancepharma.com).
For more information, please click here
BioAlliance Pharma SA
Dominique Costantini, President and CEO
Tel.: +33 1 45 58 76 01
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
Tel.: +33 6 64 18 99 59
Copyright © Business Wire 2008If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016